Investors Overview


Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

07 Jun '24
As today marks the beginning of a new board service calendar year and in accordance with the Remuneration policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, today four independent board directors received a stock option grant
07 Jun '24
The 2024 Annual and Extraordinary General Meeting (the "2024 AGM") of Alvotech (the "Company") was held on June 7, 2024, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.  Here are the main results of the 2024 AGM: The 2024 AGM approved the Company’s annual

Recent Events